No significant difference in clinically relevant findings between Pillcam® SB3 and Pillcam® SB2 capsules in a United States veteran population

Table 1 Baseline demographics

	Total	Pillcam® SB3	Pillcam® SB2	P value
Patients	260	130	130
Age (yr)	67.1 ± 10.4	68.3 ± 11.1	65.9 ± 9.5	0.061
Male gender	245 (94.2%)	122 (93.8%)	123 (94.6%)	0.790
BMI (kg/m2)	30.3 ± 6.3	30.1 ± 6.1	30.5 ± 6.4	0.618
Inpatient status	32 (12.3%)	19 (14.6%)	13 (10.0%)	0.257
Diabetes	119 (45.8%)	69 (53.1%)	50 (38.5%)	0.018
Opioid use	73 (28.1%)	31 (23.8%)	42 (32.3%)	0.129
GTT (min)	39.6 ± 47.4	37.7 ± 40.4	41.4 ± 53.4	0.971
SBTT (min)	220.4 ± 85.7	233.1 ± 82.4	208.8 ± 87.3	0.554
Inadequate preparation	33 (12.7%)	15 (11.5%)	18 (13.8%)	0.576
Incomplete exam	34 (13.1%)	22 (16.9%)	12 (9.2%)	0.066

BMI: Body mass index; GTT: Gastric transit time; SBTT: Small bowel transit time.

Table 2 Indications and findings of Pillcam^® SB3 vs Pillcam^® SB2 capsule studies

	Total	Pillcam® SB3	Pillcam® SB2	P value
	n (%)	n (%)	n (%)
Indication
Occult GIB	194 (74.6)	92 (70.8)	102 (78.5)	0.154
Overt GIB	38 (14.6)	24 (18.5)	14 (10.8)	0.079
Mass/Polyp	9 (3.5)	4 (3.1)	5 (3.8)	0.999
IBD	7 (2.7)	2 (1.5)	5 (3.8)	0.447
Other	12 (4.6)	8 (6.2)	4 (3.1)	0.237
Finding
Bleeding source1	100 (38.5)	47 (36.1)	53 (40.8)	0.444
IBD	9 (3.5)	3 (2.3)	6 (4.6)	0.500
Mass/Polyp	18 (6.9)	10 (7.7)	8 (6.2)	0.625
Change in clinical management	118 (45.4)	53 (40.8)	65 (50.0)	0.135
Clinically relevant finding	127 (48.9)	60 (46.2)	67 (51.5)	0.385

¹Blood in lumen, ulcerative disease, erosive disease, arteriovenous malformation. IBD: Inflammatory bowel disease; GIB: Gastrointestinal bleeding.